Patrick Vallance

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Sir Patrick Vallance

FRS FMedSci FRCP
Patrick Vallance Royal Society.jpg
Patrick Vallance at the Royal Society admissions day in London, July 2017
Born
Patrick John Thompson Vallance

1960 (age 58–59)
EducationTruro School
Alma materSt George's, University of London (MB, BS)
AwardsGoulstonian Lecture (1996)
Scientific career
Institutions
Websitewww.gov.uk/government/people/patrick-vallance

Sir Patrick John Thompson Vallance FRS FMedSci FRCP[1] (born 1960)[2][3] is a British medical doctor. Since March 2018 he has been the Chief Scientific Adviser to the Government of the United Kingdom. From 2012 to 2018 he served as president of research and development (R&D) at the multinational pharmaceutical company GlaxoSmithKline (GSK).[4][5][6][7]

Education[edit]

Vallance was educated at the independent Truro School in Cornwall and St George's, University of London,[5] where he gained a Bachelor of Science degree in 1981 followed by a Bachelor of Medicine, Bachelor of Surgery (MB, BS) in 1984.[2]

Career and research[edit]

From 1986-95 he taught at St George's Hospital Medical School. From 1995−2002 he was Professor at UCL Medical School, and Professor of Medicine from 2002–2006, and Head of Medicine.[2] Prior to joining GSK he was registrar of the Academy of Medical Sciences.[1]

From 2006-10 he was Head of Drug Discovery at GSK, then from 2010−12 he was Head of Medicines Discovery and Development. In 2012 he was appointed head of R&D at GSK.[8][9][10][11] Under his leadership of GSK, new medicines for cancer, asthma, autoimmune diseases and HIV infection were discovered and approved for use worldwide. He championed open innovation and novel industry-academic partnerships globally,[6][11] and maintained a strong focus on discovery of antibiotics and medicines for tropical diseases.

In March 2018, Vallance left GSK and was appointed Chief Scientific Adviser to the UK Government, where he leads the Government Office for Science.[12][13]

Vallance's personal research was in the field of vascular biology.[14][1] He made important discoveries in the field of nitric oxide[15] and endothelial cell physiology and showed that the human arterial vasculature is actively dilated by continuous release of nitric oxide.[1] He demonstrated the functional significance of this effect in different physiological and disease states and identified new pathways for regulating nitric oxide biosynthesis.[1]

Awards and honours[edit]

Personal life[edit]

Vallance was born in south-west Essex, now part of Greater London. He has an older brother (born 1957) and a younger brother (born 1962).[citation needed] He is the son of Peter Vallance. Vallance married Sophia Ann Dexter in December 1986 in the City of Westminster. They have two sons (born January 1992 and March 1994) and one daughter (born June 1997).[citation needed]

References[edit]

  1. ^ a b c d e f g h Anon (2017). "Dr Patrick Vallance FMedSci FRS". royalsociety.org. London: Royal Society. One or more of the preceding sentences incorporates text from the royalsociety.org website where:

    “All text published under the heading 'Biography' on Fellow profile pages is available under Creative Commons Attribution 4.0 International License.” --"Royal Society Terms, conditions and policies". Archived from the original on 11 November 2016. Retrieved 9 March 2016.CS1 maint: BOT: original-url status unknown (link)

  2. ^ a b c d e Anon (2017). "Vallance, Prof. Patrick John Thompson". Who's Who. ukwhoswho.com (online Oxford University Press ed.). A & C Black, an imprint of Bloomsbury Publishing plc. doi:10.1093/ww/9780199540884.013.246054. (subscription or UK public library membership required) (subscription required)
  3. ^ Anon (2017). "Patrick John Thompson VALLANCE". companieshouse.gov.uk. London: Companies House.
  4. ^ "Dr Patrick Vallance: President, R&D". gsk.com. Archived from the original on 29 July 2017.
  5. ^ a b Anon (2015). "Patrick Vallance: Inquisitive and geeky". The BMJ. 350 (mar05 5): h1144–h1144. doi:10.1136/bmj.h1144. ISSN 1756-1833. PMID 25742697.
  6. ^ a b Cressey, Daniel (2011). "Traditional drug-discovery model ripe for reform". Nature. 471 (7336): 17–18. doi:10.1038/471017a. ISSN 0028-0836.
  7. ^ Can Data Make a Medicine? - with Patrick Vallance on YouTube, Royal Institution
  8. ^ Jim Al-Khalili (2015). "The Life Scientific interviews Patrick Vallance on pharmaceuticals". bbc.co.uk. BBC.
  9. ^ Cohen, Deborah (2012). "The End of Drug Discovery". bbc.co.uk. BBC.
  10. ^ Anon (2010). "Patrick Vallance". Nature Reviews Drug Discovery. 9 (11): 834–834. doi:10.1038/nrd3307. ISSN 1474-1776. closed access
  11. ^ a b Cressey, Daniel (2011). "Deep future of drug discovery". Nature. doi:10.1038/news.2011.127. ISSN 1744-7933.
  12. ^ "Appointment of Dr Patrick Vallance as government Chief Scientific Adviser". Cabinet Office. 8 November 2017. Retrieved 9 November 2017.
  13. ^ "Patrick Vallance, President, R&D, GSK to become UK Government's Chief Scientific Adviser". GlaxoSmithKline. 8 November 2017. Retrieved 7 September 2018.
  14. ^ Patrick Vallance publications indexed by the Scopus bibliographic database. (subscription required)
  15. ^ Vallance, P.; Leone, A.; Calver, A.; Collier, J.; Moncada, S. (1992). "Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure". The Lancet. 339 (8793): 572–575. doi:10.1016/0140-6736(92)90865-Z. ISSN 0140-6736. PMID 1347093. closed access
  16. ^ "Patrick Vallance knighted in 2019 New Year's Honours". British Pharmacological Society. 29 December 2018. Retrieved 7 February 2019.
Business positions
Preceded by
 Head of R&D at GSK
January 2012 – March 2018 		Succeeded by
Hal V. Barron
Government offices
Preceded by
Sir Mark Walport 		Government Chief Scientific Adviser
2018–present 		Incumbent
Retrieved from "https://en.wikipedia.org/w/index.php?title=Patrick_Vallance&oldid=926926119"